Participant flow

Dasatinib In Waldenström Macroglobulinemia · Source last updated 2024-03-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   \-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle. Dasatinib: Oral Study Drug(s): * Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day. * This will continue for up to 24 cycles. Dasatinib: Oral, daily, dosing per protocol, once a day for cycle

   id

   FG000

   title

   Dasatinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Lack of Efficacy

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice